On-Demand CE Course on Effective Novel Gene Therapies in Hemophilia; Implementing Value-Based Coverage Policies

September 1, 2021

Novel gene therapies are of particular interest in treating hemophilia. Despite promises of efficacy and even curing the disease for which they are intended using a single treatment, the high cost of these gene therapies alarms payers. A continuing education (CE) course offered by the National Hemophilia Foundation, Impact Education, and Medical Education Resources provides an overview of gene therapies used in hemophilia and discusses their outcomes. The course also covers the costs associated with treatment and includes an in-depth discussion on approaches to pricing and payer coverage.

“While the cost of gene therapy for hemophilia is anticipated to be sizably greater than that of currently prescribed agents, many opinion leaders anticipate it to be a “once in a lifetime treatment.” As a result, the anticipated high cost of gene therapy will likely be offset by the avoidance of continued factor replacement therapy and other components of health care resource utilization. Still, the prospect of a significantly larger, albeit potentially one-time drug acquisition cost presents a challenge for payers and the standard models used to cover and pay for prescription drugs.” Learn more here.

Share This Story!